相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Progressive Multifocal Leukoencephalopathy Associated With Immunosuppressive Therapy in Rheumatic Diseases
Eamonn S. Molloy et al.
ARTHRITIS AND RHEUMATISM (2012)
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry
Fabiola Atzeni et al.
AUTOIMMUNITY REVIEWS (2012)
Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS)
Niklas Schmedt et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents
Jeffrey R. Curtis et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
D. E. Furst et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0
Loreto Carmona et al.
RHEUMATOLOGY (2011)
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
James B. Galloway et al.
RHEUMATOLOGY (2011)
Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis
Fabrizio Conti et al.
RHEUMATOLOGY (2011)
Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label
Candido Diaz-Lagares et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
Hans-Peter Tony et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Consensus statement of the spanish society of rheumatology on risk management of biologic therapy in rheumatic patients
Juan Gomez Reino et al.
REUMATOLOGIA CLINICA (2011)
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology
William G. Dixon et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Risk Factors for Severe Infections in Patients With Rheumatoid Arthritis Treated With Rituximab in the AutoImmunity and Rituximab Registry
J. -E. Gottenberg et al.
ARTHRITIS AND RHEUMATISM (2010)
Safety and Efficacy of Rituximab in Systemic Lupus Erythematosus
Benjamin Terrier et al.
ARTHRITIS AND RHEUMATISM (2010)
Infections in polymyositis and dermatomyositis: analysis of 192 cases
I-Jung Chen et al.
RHEUMATOLOGY (2010)
Predictors of major infections in systemic lupus erythematosus
Guillermo Ruiz-Irastorza et al.
ARTHRITIS RESEARCH & THERAPY (2009)
A Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases
Manuel Ramos-Casals et al.
MEDICINE (2008)
All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists
Loreto Carmona et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003
Y Alamanos et al.
RHEUMATOLOGY (2006)
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists
L Carmona et al.
ARTHRITIS AND RHEUMATISM (2005)
Predictors of infection in rheumatoid arthritis
MF Doran et al.
ARTHRITIS AND RHEUMATISM (2002)
Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis
BJ Fessler
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2002)
分享论文
